1. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. (18th October 2016) Authors: Borte, M.; Kriván, G.; Derfalvi, B.; Maródi, L.; Harrer, T.; Jolles, S.; Bourgeois, C.; Engl, W.; Leibl, H.; McCoy, B.; Gelmont, D.; Yel, L. Other Names: Weinberger Birgit guestEditor.; Akbar Arne guestEditor. Journal: Clinical and experimental immunology Issue: Volume 187:Number 1(2017:Jan.) Page Start: 146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Issue 2 (27th November 2016) Authors: Mullins, E. S.; Stasyshyn, O.; Alvarez‐Román, M. T.; Osman, D.; Liesner, R.; Engl, W.; Sharkhawy, M.; Abbuehl, B. E. Journal: Haemophilia Issue: Volume 23:Issue 2(2017) Page Start: 238 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗